课题基金 / 基金详情

Investigating HIF1-alpha Signaling to Identify Predictive Markers and Therapeutic Targets in Desmoid-Type Fibromatosis

Investigating HIF1-alpha Signaling to Identify Predictive Markers and Therapeutic Targets in Desmoid-Type Fibromatosis
研究 HIF1-α 信号传导以识别硬纤维瘤型纤维瘤病的预测标记物和治疗靶点
批准号:
10357768
负责人:
Aimee Marie Crago
金额:
$55.81万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-03-01 至 2025-02-28

项目摘要

项目成果

Aimee Marie Crago的其他基金

相关文献

中文摘要
翻译
韧带样型纤维瘤病是一种间叶性肿瘤,不会进展为高级别疾病或 转移瘤。手术是硬纤维瘤的标准治疗方法,但对于有广泛疾病的患者,手术是 可能会导致像肿瘤本身一样的并发症,大约30%的患者有局部复发。 由于这些和其他原因,主动观察被开给越来越多的患有 无症状的疾病。然而,硬纤维样瘤的结果是高度可变的;观察到一半的硬纤维样瘤 不会超过两年,当其他硬纤维瘤生长时,一个子集会自发退化 毫不留情。局部侵袭性肿瘤可引起严重症状:硬纤维瘤引起的疼痛和痉挛 腹部韧带样瘤的四肢和肠瘘及死亡。一旦出现症状,可能 很难逆转。因此,需要在推荐ACTIVE之前使用工具来预测结果 观察。几乎所有的结缔组织都含有ctnnb1突变,这种突变会结构性地激活基因产物β- 连环蛋白,但广泛的遗传分析未能发现任何其他可能 患者预后变化的潜在原因。这一建议建立在初步结果的基础上,该结果表明β-连锁素 通过包括低氧诱导因子在内的非典型下游靶点促进韧带样癌的发生 α(HIF1α)。HIF1α蛋白水平和促纤维样细胞增殖也被激活的PDGFRβ所促进, 这可能解释了为什么索拉非尼,一种PDGFRβ的抑制剂,在其他受体酪氨酸激酶中, 结缔组织中的活动。基于这些和其他初步数据,我们假设HIF1α介导 来自PDGFRβ的有丝分裂信号依赖于激活的β-连环蛋白。我们建议调查 这条途径和其他途径在结缔组织生物学中的作用,并利用所获得的洞察力来识别和测试潜力 硬纤维瘤生长的生物标志物。在目标1中,我们试图确定HIF1α和β-连环蛋白在 介导促纤维细胞生长因子受体β信号转导和增殖。在《目标2》中,我们进行了高度聚焦的筛选以 确定韧带细胞增殖所必需的其他基因和可用药途径。我们会 然后测试它们是在PDGFRβ/β-catenin/Hif1α轴的上游起作用,还是独立于这个轴起作用。 最后,在目标3中,我们建议使用作为第二阶段试验的一部分收集的活组织标本来检查 在积极观察期间,韧带样变的进展可以通过PDGFRβ/β的标志物来预测。 连环蛋白/缺氧诱导因子1α通路或AIMS 1和2中定义的其他通路。 生物标记物将帮助临床医生确定针对个别硬纤维瘤患者的最佳治疗途径。在……里面 此外,通过阐明韧带样癌发生的分子基础,这项工作可能会识别出新的 这种疾病的治疗目标。因为β-连环蛋白的异常活性可以在广泛的 对于肿瘤,我们的结果可能会提供洞察,也影响我们对其他癌症的方法。
英文摘要
Desmoid-type fibromatosis is a mesenchymal tumor that does not progress to high-grade disease or metastasize. Surgery was the standard treatment for desmoids, but in patients with extensive disease, surgery can lead to complications as morbid as the tumors themselves, and ~30% of patients have local recurrence. For these and other reasons, active observation is prescribed to an increasingly large subset of patients with asymptomatic disease. Desmoid outcomes, however, are highly variable; under observation half of desmoids do not progress over two years and a subset will regress spontaneously, while other desmoids grow relentlessly. Locally aggressive tumors can cause severe symptoms: pain and contracture from desmoids in the extremities and intestinal fistulization and death from abdominal desmoids. Once present, symptoms can be difficult to reverse. Therefore, there is need for tools to predict outcome prior to recommending active observation. Nearly all desmoids contain CTNNB1 mutations that constitutively activate the gene product, β- catenin, but extensive genetic analyses have failed to identify any additional genetic alterations that may underlie variations in patient prognosis. This proposal builds upon preliminary results suggesting that β-catenin promotes desmoid oncogenesis through non-canonical downstream targets, including hypoxia-inducible factor α (HIF1α). Both HIF1α protein levels and desmoid cell proliferation are also increased by activated PDGFRβ, which may explain the fact that sorafenib, an inhibitor of PDGFRβ among other receptor tyrosine kinases, has activity in desmoids. Based on these and other preliminary data, we hypothesize that HIF1α mediates mitogenic signals from PDGFRβ in a manner dependent on activated β-catenin. We propose to investigate the role of this and other pathways in desmoid biology and to use the insight gained to identify and test potential biomarkers of desmoid tumor growth. In Aim 1, we seek to determine the roles of HIF1α and β-catenin in mediating PDGFRβ signaling and proliferation in desmoid cells. In Aim 2, we perform highly focused screens to identify additional genes and druggable pathways that are necessary for desmoid cell proliferation. We will then test whether they act upstream of a PDGFRβ/β-catenin/HIF1α axis or act independently of this axis. Finally, in Aim 3, we propose to use biopsy specimens, collected as part of a phase II trial, to examine whether desmoid progression during active observation can be predicted by markers from the PDGFRβ/β- catenin/HIF1α pathway or other pathways defined in Aims 1 and 2. We expect the proposed studies to identify biomarkers that will help clinicians to identify optimal therapeutic pathways for individual desmoid patients. In addition, by elucidating the molecular basis of oncogenesis in desmoids, this work may identify novel therapeutic targets for the disease. Because aberrant β-catenin activity can be observed in a wide range of neoplasms, our results may provide insight that affects our approach to other cancers as well.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating HIF1-alpha Signaling to Identify Predictive Markers and Therapeutic Targets in Desmoid-Type Fibromatosis
  • 批准号:
    10576913
  • 项目类别:
  • 资助金额:
    $54.69万
  • 财政年份:
    2020
  • 负责人:
    Aimee Marie Crago
  • 依托单位: